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Scinderin is a calcium-dependent actin filament-severing protein recently discovered in the chromaffin cells of adrenal medulla. In view of the wide 
tissue distribution of gelsolin, another actin filament-severing protein, experiments were performed to determine the tissue expression of scinderin. 
Extracts prepared from different bovine tissues were tested by actin-DNase I Sepharose 4B-binding procedure and immunoprecipitation followed 
by immunoblotting with scinderin and gelsolin antibodies. Among the tissues tested, scinderin was found to be present in the adrenal medulla, 
brain, anterior and posterior pituitaries, kidney, salivary gland and testis. Scinderin was not found in liver, plasma, skeletal and heart muscles. 
Gelsohn was expressed in all of the above tissues. The results suggest that scinderin seems to be restricted to tissues with high secretory activity. 
Scinderin; Actin; Gelsolin; Actin-binding protein 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Gelsolin is an actin filament-severing and capping 
protein found in many tissues [1,2]. It was first iden- 
tified in rabbit lung macrophages [3] and subsequently 
found in many mammalian cells 141 including chromaf- 
fin cells [5,6]. Brevin is a slightly larger form of gelsolin 
present in plasma and containing a 25 amino acid ex- 
tension at its NHz-terminus [7]. The liver is the main 
source of this circulating gelsolin. 
2.1. Preparation of tissue extracts and actin-DNase I Sepharose 48 
procedure 
In our earlier studies on the isolation and 
~haracter~ation of chromaffin cell gelsolin, we observ- 
ed that another protein was eluted by EGTA- 
containing buffers together with gelsolin from the 
DNase I affinity columns [5,6]. This protein was later 
found to be another calcium-dependent actin filament- 
severing protein [8,9]. The name of scinderin has been 
proposed for this protein and studies on its isolation 
and characterization have been published from our 
laboratory [8,9]. In view of the wide tissue distribution 
of gelsolin, studies were carried out to determine the 
tissue expression of scinderin. 
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In order to test the tissue distribution pattern of scinderin and 
gelsolin, a partial purification procedure was used. Twenty-five 
grams each of the following bovine tissues - adrenal medulla, brain, 
heart muscle, skeletal muscle, kidney, liver and 100 ml of plasma - 
were tested. Except for the plasma, the rest of the tissues were washed 
in ice-cold Locke’s solution [lo] to remove the blood and homogenis- 
ed in the same homogenisation buffer used for scinderin purification 
[9] with the omission of 300 mM KC1 (1 g tissue in 4 ml solution), us- 
ing a Sorval omnimixer. The homogenates were centrifuged at 1000 
x g for 10 min. The resultant supernatants and the plasma were then 
centrifuged at 100000 x g for 60 min and dialysed against 20 mM im- 
idazole (pH 7.5), 1 mM DTT, 0.25 mM PMSF and 1 mM CaClz. 
After the dialysis step CaClz and Na-ATP were added to obtain a 
final concentration of 2 mM and 0.5 mM, respectively. DNase I 
coupled to Sepharose 4B beads were prepared as described by Bader 
et al. [6] and saturated with G-actin. The gels were pre-equilibrated 
with 20 mM imidazole @H 7.5), 1 mM DTT, 0.25 mM PMSF, 1 mM 
CaClz and 0.5 mM Na-ATP. Supernatants obtained above were mix- 
ed with DNase I Sepharose 4B gel and incubated under rotation over- 
night at 4°C. Each DNase I Sepharose 4B gel batch used had an 
actin-binding capacity equal to 600 nmol of actin. The preparations 
were centrifuged at 5000 x g for 20 min, the gel sediments were wash- 
ed several times with the same buffer containing 0.6 M NaCI. Each 
time the same centrifugation forces were used to sediment he gel. 
The ~icium-dependent actin-binding proteins were eluted by 
washing the gels with 20 mM imidazole (pH 7.5), 0.25 mM PMSF, 
10 mM EGTA, 1 mM DTT and 0.5 mM Na-ATP. Samples from the 
eluents were used for immunoblotting. 
Abbreviations: SDS-PAGE, sodium dodecylsulfate polyacrylamide 
gel electrophoresis; Tris-HCl, tris(hydroxym~hyl)methylamine-HCl; 
DTT, dithiothreitol; EGTA, ethyleneglycol-bis-~-amin~thylether)-- 
N,N,N’,N’-tetraacetic acid; PMSF, phenylmethylsulfonyl fluoride; 
ATP, adenosine triphosphate DNase, desoxyribonuclease 
2.2. Preparation of scinderin 
Scinderin was purified from the adrenal medulla following a four- 
step chromatography procedure previously described [9]. 
2.3. Source of antibodies 
Polyclonal antibodies against gelsolin and scinderin were raised in 
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rabbits against purified antigens as described previously [6,9]. 
Scinderin and gelsolin antibodies have been previously characterized 
;a~;: ante~;;i;~~erior brain kidney 
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2.4. Electrophoresis 
97.4 
Polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
according to Doucet and Trifar6 [l 11. 66.2 I 
(-4 4 -SC 
2.5. Immunoprecipitation 
Three grams of each tissue to be tested were homogenized in 5 ml 
of buffer A (mM: Tris-HCl 20 (pH 7.5), KC1 300, MgClz 500, DTT 
0.1; soybean trypsin inhibitor (10 pg/ml) and leupeptin (1 fig/ml)) 
and centrifuged at 5000 x g for 30 min. The supernatants thus ob- 
tained were further centrifuged at 100000 x g for 60 min. Three ml 
of the supernatants were then incubated for 60 min with 240 ~1 of a 
protein A Sepharose CL-4B (Sigma) suspension that had been in- 
cubated previously with scinderin antibody for 30 min (1 ml of 5% 
protein A in buffer B plus 3 ml of 1: 20 dilution in buffer B of 
scinderin antiserum). After this incubation period, samples were cen- 
trifuged at 5000 x g for 10 min and the pellets thus obtained were 
washed 3 times with buffer B (mM: Tris-HCl20 (pH 7.5), EGTA 0.1, 
KC1 20, DTT 0.1; soybean trypsin inhibitor (10 pg/ml) and leupeptin 
(1 pg/ml)). The sediments were then boiled in 150~1 of buffer C 
(mM: Tris-HCl 70 (pH 8.0), EGTA 1, 3% SDS, 10% glycerol, 10% 
,&mercaptoethanol) for 5 min and then centrifuged at 5000 x g for 
10 min. The supernatants were boiled in electrophoresis sample buf- 
fer for 2 min and electrophoresis and immunoblotting were perform- 
ed as described above. The immunoprecipitation technique used in 
the experiments allowed the determination of at least 5 pmol of 
scinderin per sample with a recovery of 80%. 
Fig. 1. Tissue expression of scinderin. Samples (15Oyg protein) of 
concentrated EGTA eluents obtained as described in section 2 were 
subjected to 10% SDS-PAGE and transferred to nitrocellulose 
membranes. Bovine adrenal medullary extract was used as control. 
Bovine anterior and posterior pituitary glands, brain and kidneys 
were tested and found to displace positive immunoreactivity when 
tested against scinderin antibodies at antibody dilution of 1: 500. The 
position of scinderin in the immunoblots is indicated by arrowheads. 
the concentration of scinderin in the adrenal medulla 
was about 1 nmo1/25 g tissue. All samples used in these 
studies were prepared from 25 g of each tested tissue. 
Moreover, other actin-binding proteins were found in 
the EGTA eluents obtained from tissues devoid of 
scinderin and in order to discard the possibility that 
these proteins have blocked the binding or adsorption 
of scinderin on the affinity gels, the following experi- 
ment was performed. Cytosol preparations for liver, 
heart and skeletal muscles and 100 ml plasma were mix- 
2.6. Immunoblotting procedures 
The protocol for immunoblotting was based on the technique of 
Towbin et al. [12]. Protein samples were processed for immunoblot- kDa 12 3 4 56 7 6 
ting as described previously [13,14]. 
200 
3. RESULTS 
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Early experiments from our laboratory demonstrated 
that scinderin was too diluted to be detected by im- 
munoblotting in cytosolic fractions [9]. Consequently, 
it was necessary to obtain partially purified prepara- 
tions of scinderin from the tissues prior to testing. The 
antibodies used in these studies were raised against 
bovine adrenal medullary scinderin and they did not 
cross-react with rat adrenal medujlary scinderin. Con- 
sequently, only bovine tissues were used in the ex- 
periments. Four different experiments were performed 
for each of the following tissues: adrenal medulla, 
brain, kidney, anterior and posterior pituitaries, 
skeletal and heart muscles, liver and plasma. Adrenal 
medulla, a tissue known to contain both gelsolin and 
scinderin [5,6,8,9] was used as control. Immunoblot- 
ting tests performed on the EGTA eluents from the ac- 
tin DNase I Sepharose 4B gel demonstrated that in 
addition to adrenal medullary tissue, scinderin was ex- 
pressed in anterior and posterior pituitaries, brain and 
kidney, with this latter tissue containing less scinderin 
than the others (Fig. 1). Immunoblotting tests for 
scinderin were negative for skeletal and heart muscles 
and for liver and plasma. This was not due to a low 
capacity of the affinity gel since (i) up to 600 nmol of 
actin-binding proteins could be retained per gel and (ii) 
Qi?4 
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Fig. 2. Lack of interference of actin-binding proteins on scindering 
adsorption on DNase I Sepharose 4B gels. 25 g of heart (lanes 1 and 
5) and skeletal (lanes 2 and 6) muscles, liver (lanes 3 and 7) and 
100 ml of plasma (lanes 4 and 8) were processed as described in 
section 2. 6 ml (2 g) of adrenal medullary cytosol were added to each 
of the above-described preparations and this was followed by 
incubation with DNase I Sepharose 4B gels overnight. EGTA eluents 
(15Opg protein each) were subjected to SDS-PAGE, transferred to 
nitrocellulose membranes and stained with amido black 10B (lanes 
I-4) or incubated with scinderin antibodies (1: 500 dilution, lanes 
5-8). First lane (St) shows molecular weight standards. An 
arrowhead indicates the position of scinderin (SC). 
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Fig. 3. Presence of gelsolin and/or brevin in adrenal meduilary tissue 
and tissues (skeletal and heart muscles, liver and plasma) which do 
not contain scinderin. Samples (15Opg protein) of EGTA eluents 
obtained under similar conditions to those described in tegend to 
Fig. 1, were subjected to SDS-PAGE and then transferred to 
nitrocellulose membranes and tested with gelsolin antibody (1: lOOft 
dilution). The positions of gelsolin (G) and brevin (B) are indicated 
by arrows. 
ed with 6 ml (2 g) of adrenal medullary cytosol and 
subsequently added to the DNase I Sepharose 4B gels. 
EGTA eluents from DNase I Sepharose 4B gels were 
subjected to SDS-PAGE followed by transfer to 
nitrocellulose membranes and immunoblotting with 
scinderin antibodies. In every case, adrenal medullary 
scinderin was detected in the EGTA eluents (Fig. 2), 
thus indicating that there was no interference with the 
binding of scinderin to the affinity gel by other actin- 
binding proteins present in the preparations. In one of 
the experiments, transferred proteins were incubated 
with gelsolin antibodies, in addition to anti-scinderin. 
Fig. 3 shows that all tissues (skeletal and heart muscles, 
liver and plasma) that did not express cinderin, did ex- 
press gelsolin. Moreover, liver and plasma also express- 
ed brevin (Fig. 3). In order to confirm the above results 
another technique was also used. Immunoprecipitation 
studies were then performed on cytosolic samples 
prepared from bovine tissues. The antibody 
precipitated scinderin from those tissues found to be 
positive in the above experiments and, in addition, tests 
on salivary gland and testis also demonstrated the 
presence of scinderin in these tissues (Fig. 4A). Again 
in these immunoprecipitation studies, liver, plasma as 
well as skeletal and heart muscles were found to be 
negative (Fig. 4A). Experiments in which scinderin ali- 
quots (0.5, 5, 50 and 500 pmol) were added to liver 
samples demonstrated that this actin filament-severin 
A kDa 
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Fig. 4. (A) Xmmunoprecipitation tests performed with scinderin 
antibody. The immunopr~ipitations studies were carried out as 
described in section 2. The antibody did not precipitate any proteins 
from skeletal (sm) and heart muscles (hm) as well as liver (1) and 
plasma (p) preparations whereas scinderin was found in 
immunoprecipitates from adrenal medulla (am), salivary gland (sg), 
kidney (k) and testis (t). (B) In order to test the sensitivity of the 
method, decreasing amounts of scinderin (pmol: lanes 2 and 2’, 500; 
lanes 3 and 3’) 50; lanes 4 and 4’, 5; and lane 5,0.S) were subjected 
to the immunoprecipitation procedure. Scinderin was incubated 
alone (lanes 2-5) or in the presence of 3 ml of liver cytosol (30 mg 
protein; lanes 2’-4’). Lane 1 corresponds to 50 pmol of scinderin 
applied directly to the SDS-gel. 
protein could be precipitated in the presence of liver 
cytosolic proteins (Fig. 4B). The technique of im- 
munopre~ipitation used in the experiments can easily 
detect 5 pmols scinderin (Fig. 4B); the recovery of 
scinderin was 80% in the absence and 60% in the 
presence of liver cytosolic proteins. 
4. DISCUSSION 
Early work from our laboratory demonstrated the 
presence in chromaffin cells of gelsolin and scinderin, 
two Ca2+-activated actin filament-severing proteins 
[.5,6,8,9]. Our studies also demonstrated that scinderin 
is a structurally different protein from gelsolin [8,9]. 
Scinderin and gelsolin have different molecular 
weights, isoelectric points, amino acid composition and 
yield different peptide maps after limited proteolytic 
digestion. Moreover, scinderin antibodies do not cross- 
react with gelsolin and gelsolin antibodies fail to 
recognize scinderin [8,9]. 
The present experiments using two different techni- 
ques (actin-DNase I-Sepharose 4B procedure and im- 
munoprecipitation) showed that scinderin was strongly 
expressed in addition to adrenal medulla in brain, 
salivary glands, anterior and posterior pituitaries. 
Renal tissue and testis, although found positive were 
found to contain a much reduced amount of scinderin. 
The results also showed that scinderin is absent from 
skeletal and heart muscles, liver and plasma, tissues 
known to contain gelsolin. Since scinderin was not 
detected in these tissues and the sensitivity of the im- 
munoprecipitation method used was of 5 pmol, it can 
be concluded that skeletal and heart muscles, liver and 
plasma do not contain any scinderin or, if they do, their 
content is less than 5 pmol/25 g tissue. This concentra- 
tion of scinderin would be 200 times lower than that 
present in the adrenal medulla (1000 pmo1/25 g). The 
211 
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present results showing different tissue expressions for 
gelsolin and scinderin add another fact to the list of dif- 
ferences between these two actin filament-severing pro- 
teins. Consequently, the tissue localization of scinderin 
is more restricted than that of gelsolin. This was not 
unexpected since villin, another actin filament-severing 
protein of the gelsolin family, is restricted to tissues 
whose main function is reabsorption, such as intestine, 
kidney, biliary and pancreatic ducts [15,16]. Scinderin 
seems to be expressed in neuronal and endocrine 
tissues; systems in which secretion is a main function. 
Early work from this laboratory also demonstrated that 
scinderin is localized in the subplasmalemmal rea of 
the chromaffin cell [9]. This is the same area that has 
been shown to contain actin [17,18]. Moreover, work 
from our [ 17,191 as well as from other laboratories [ 181 
have indicated that this network of actin is disrupted 
during stimulation, thus removing a barrier to the 
movement of secretory vesicles to releasing sites on the 
inner surface of the plasma membrane. Because of the 
localization of scinderin in the subplasmalemmal 
region of the chromaffin cell and of its activation by 
Ca2+, one is tempted to speculate that cell stimulation 
and Ca2+ entry activate actin filament severing proteins 
such as scinderin with a consequent breakdown of the 
actin subplasmalemmal network. This attractive 
hypothesis is now being tested in our laboratory. 
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